Michael J. Morris
Michael J. Morris
Verified email at - Homepage
Cited by
Cited by
Integrative clinical genomics of advanced prostate cancer
D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ...
Cell 161 (5), 1215-1228, 2015
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical …
HI Scher, S Halabi, I Tannock, M Morris, CN Sternberg, MA Carducci, ...
Journal of clinical oncology 26 (7), 1148-1159, 2008
Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer
O Sartor, J De Bono, KN Chi, K Fizazi, K Herrmann, K Rahbar, ST Tagawa, ...
New England Journal of Medicine 385 (12), 1091-1103, 2021
Organoid cultures derived from patients with advanced prostate cancer
D Gao, I Vela, A Sboner, PJ Iaquinta, WR Karthaus, A Gopalan, ...
Cell 159 (1), 176-187, 2014
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3
HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ...
Journal of Clinical Oncology 34 (12), 1402-1418, 2016
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
HI Scher, TM Beer, CS Higano, A Anand, ME Taplin, E Efstathiou, ...
The Lancet 375 (9724), 1437-1446, 2010
Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial
TK Choueiri, S Halabi, BL Sanford, O Hahn, MD Michaelson, MK Walsh, ...
Journal of Clinical Oncology 35 (6), 591-597, 2017
Analysis of the prevalence of microsatellite instability in prostate cancer and response to immune checkpoint blockade
W Abida, ML Cheng, J Armenia, S Middha, KA Autio, HA Vargas, ...
JAMA oncology 5 (4), 471-478, 2019
Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer
DC Danila, MJ Morris, JS De Bono, CJ Ryan, SR Denmeade, MR Smith, ...
Journal of Clinical Oncology 28 (9), 1496-1501, 2010
Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making
W Abida, J Armenia, A Gopalan, R Brennan, M Walsh, D Barron, D Danila, ...
JCO precision oncology 1, 1-16, 2017
Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate …
WK Kelly, S Halabi, M Carducci, D George, JF Mahoney, WM Stadler, ...
Journal of Clinical Oncology 30 (13), 1534-1540, 2012
Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer
S Halabi, CY Lin, WK Kelly, KS Fizazi, JW Moul, EB Kaplan, MJ Morris, ...
Journal of Clinical Oncology 32 (7), 671-677, 2014
Phase II study of lutetium-177–labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer
ST Tagawa, MI Milowsky, M Morris, S Vallabhajosula, P Christos, ...
Clinical cancer research 19 (18), 5182-5191, 2013
Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer
S Halabi, WK Kelly, H Ma, H Zhou, NC Solomon, K Fizazi, CM Tangen, ...
Journal of clinical oncology 34 (14), 1652-1659, 2016
Tumor localization of 16β-18F-fluoro-5α-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer
SM Larson, M Morris, I Gunther, B Beattie, JL Humm, TA Akhurst, RD Finn, ...
Journal of Nuclear Medicine 45 (3), 366-373, 2004
Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free …
TK Choueiri, C Hessel, S Halabi, B Sanford, MD Michaelson, O Hahn, ...
European journal of cancer 94, 115-125, 2018
Germline BRCA Mutations Denote a Clinicopathologic Subset of Prostate Cancer
DJ Gallagher, MM Gaudet, P Pal, T Kirchhoff, L Balistreri, K Vora, J Bhatia, ...
Clinical cancer research 16 (7), 2115-2121, 2010
Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
B Nguyen, C Fong, A Luthra, SA Smith, RG DiNatale, S Nandakumar, ...
Cell 185 (3), 563-575. e11, 2022
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer
DE Rathkopf, MJ Morris, JJ Fox, DC Danila, SF Slovin, JH Hager, PJ Rix, ...
Journal of clinical oncology 31 (28), 3525-3530, 2013
The system can't perform the operation now. Try again later.
Articles 1–20